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Abstract 
Background: Insomnia is associated with increased cardiovascular disease (CVD) risk in the 
general population and is highly prevalent in people with HIV. The CVD risk conferred by 
insomnia in the HIV population is unknown. 
Methods: Using the Veterans Aging Cohort Study-Survey Cohort, insomnia symptoms were 
measured and dummy coded with the item, “Difficulty falling or staying asleep?” (5-point scale 
from no difficulty to bothers a lot). Incident CVD event ICD-9 codes (acute myocardial 
infarction, stroke, or coronary artery revascularization) were identified with VA and Medicare 
administrative data and VA fee-for-service data. Those with baseline CVD were excluded. 
Results: HIV-infected (N=3,108) veterans had a median follow-up time of 10.8 years, during 
which 267 CVD events occurred. Compared to HIV-infected veterans with no difficulty falling 
or staying asleep, HIV-infected veterans bothered a lot by insomnia symptoms had an increased 
risk of incident CVD after adjusting for demographics (HR=1.64, 95%CI=1.16-2.31, p=.005), 
CVD risk factors (HR=1.62, 95%CI=1.14-2.30, p=.007), additional potential confounders 
(hepatitis C infection, renal disease, anemia, alcohol use, cocaine use; HR=1.70, 95%CI=1.19-
2.43, p=.003), and HIV-specific factors (HIV-1 RNA, CD4+ T-cell count, ART; HR=1.66, 
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95%CI=1.16-2.37, p=.005). Additional adjustment for non-benzodiazepine sleep medication 
(HR=1.62, 95%CI=1.13-2.32, p=.009) did not attenuate the association; however, it fell short of 
significance at p < .01 after adjustment for depressive symptoms (HR=1.51, 95%CI=0.98-2.32, 
p=.060) or antidepressant medication (HR=1.51, 95%CI=1.04-2.19, p=.031). 
Conclusion: Highly bothersome insomnia symptoms were significantly associated with incident 
CVD in HIV-infected veterans, suggesting that insomnia may be a novel, modifiable risk factor 
for CVD in HIV. 
Key Words: HIV, cardiovascular disease, insomnia, sleep disturbance, Veterans, VACS, 
prospective study 
 
Introduction 
 Antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) into 
a chronic, manageable condition. However, the decrease in AIDS-related mortality has been 
accompanied by an increase in the prevalence of non-communicable chronic diseases, including 
cardiovascular disease (CVD). In fact, CVD is a leading cause of death among HIV-infected 
adults.1-3 A 2012 meta-analysis reported a 1.6-2.0 times greater risk of CVD in HIV-infected 
versus uninfected adults.4 A portion of the elevated HIV-CVD risk has been attributed to the 
HIV virus,5-7 ART treatment,4,8,9 and both traditional10 and non-traditional (e.g., renal disease 
and hepatitis C)11,12 CVD risk factors. Even so, excess CVD risk is still observed among HIV-
infected adults after controlling for HIV viral load, ART use, and CVD risk factors13 and is 
observed in those with optimal CVD risk profiles.14 Other factors thought to contribute to the 
excess CVD risk in HIV include altered immune, coagulation, and endothelial function.15 While 
these biological mechanisms improve with ART, markers of these factors do not fully normalize 
among virologically-suppressed HIV-infected adults.16-22 Thus, there is a need to identify novel, 
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modifiable risk factors for HIV-CVD with the potential to improve these dysregulated 
mechanisms. 
General population research provides three lines of evidence suggesting that insomnia 
may be a novel risk factor for HIV-CVD. First, insomnia is an independent risk factor for CVD 
in the general population. Meta-analytic findings show that adults with elevated insomnia 
symptoms have an increased risk for CVD (risk ratio [RR] = 1.45),23 including coronary heart 
disease (RR = 1.28), myocardial infarction (RR = 1.41), stroke (RR = 1.55), and CVD-related 
mortality (RR = 1.33), after adjustment for traditional CVD risk factors.24 In addition, a meta-
analysis examining individual insomnia symptoms found that difficulty initiating sleep, difficulty 
maintaining sleep, and non-restorative sleep were associated with increased CVD risk (RRs = 
1.27, 1.11, and 1.18, respectively).25 Moreover, recent evidence suggests that the atherogenic 
effects of insomnia are independent from that of sleep apnea.26,27 
Second, intriguing evidence suggests that insomnia may be a causal risk factor for CVD 
in the general population. The largest randomized control trial (RCT) of behavioral interventions 
for insomnia by Irwin et al.28 found that older adults with insomnia treated with cognitive 
behavioral therapy for insomnia (CBT-I), versus an educational sleep seminar, had a 
significantly reduced risk (odds ratio = 0.26) of elevated C-reactive protein (CRP; 3.0 mg/L), an 
inflammatory marker predictive of incident CVD.29 The authors concluded that CBT-I is a viable 
option for modifying an inflammatory marker of CVD risk. 
Third, insomnia may be a novel driver of putative biological mechanisms underlying 
HIV-CVD. In addition, insomnia has been associated with altered immune function,30 systemic 
inflammation,31 and altered coagulation.32-38  
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 Despite the extensive literature supporting an insomnia-CVD association in the general 
population and the high insomnia/sleep disturbance prevalence among HIV-infected adults,39,40 
to our knowledge, no study has examined whether indicators of insomnia predict incident CVD 
in HIV-infected adults. Thus, the study purpose was to test whether insomnia symptoms 
independently predict incident CVD events among HIV-infected veterans.  
 
Methods 
Study Design and Setting 
 We utilized the HIV-infected sample from the Veterans Aging Cohort Study (VACS)-
Survey Cohort – a prospectively enrolled observational longitudinal survey cohort of HIV-
infected veterans and 1:1 matched uninfected veterans on age, sex, race/ethnicity, and clinical 
site.41 The VACS-Survey Cohort undergoes continuous enrollment, beginning in June of 2002. 
We defined the baseline period as -ever to +6 months of the enrollment date. All participants 
were followed until the occurrence of a CVD event, death, or the last date of our follow-up 
period (December 25, 2014). From the total HIV-infected sample of the VACS-Survey Cohort 
(N = 3,714), we excluded: (1) veterans with pre-existing CVD International Classification of 
Diseases, Ninth Revision [ICD-9] codes for acute myocardial infarction [AMI], unstable angina, 
cardiovascular revascularization, stroke or transient ischemic attack, peripheral vascular disease, 
or heart failure in the VA, Medicare, and Medicaid administrative data or VA fee-for-service 
data during our baseline period (n = 523); (2) veterans missing insomnia symptoms data (n = 
40); (3) veterans missing more than two items on the Patient Health Questionnaire-9 (PHQ-9; n 
= 40); and (4) veterans with coding errors (i.e., negative follow-up time; n = 3). Our final sample 
consisted of 3,108 HIV-infected veterans. 
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Measures and Procedures 
 Baseline insomnia symptoms. Insomnia symptoms were assessed at enrollment by the 
insomnia symptom item of the VACS HIV Symptom Index – a 20-item, self-report questionnaire 
assessing the frequency and bother of common symptoms in HIV-infected adults exposed to 
multidrug ART and protease inhibitors.42 Participants were asked to indicate what response best 
described their experience of each symptom over the past four weeks using the following 
options: 0 = “I do not have this symptom” or “I have this symptom and…” 1 = “it doesn’t bother 
me,” 2 = “it bothers me a little,” 3 = “it bothers me,” 4 = “it bothers me a lot.” We used 
responses to the insomnia item – “Difficulty falling or staying asleep?” – to create a 5-level 
insomnia symptoms variable. From this variable, four dummy coded variables were created with 
the “No Difficulty Falling or Staying Asleep” group as the reference category. Although our 
insomnia symptoms measure is a single-item, one-time assessment, data from the VACS-Survey 
Cohort suggests that this measure is moderately stable over time and thus likely captures 
participants' long-term exposure to insomnia symptoms. Specifically, when correlating responses 
to this item across VACS-Survey Cohort follow-ups occurring between 2002-2011, we observed 
medium positive correlations (rs range: 0.44-0.60; all ps < .001) between adjacent follow-ups. 
Incident cardiovascular disease events. CVD events were identified using VA and 
Medicare administrative data and VA fee-for-service data. We defined an incident CVD event as 
first occurrence of at least one inpatient ICD-9 code for AMI or stroke or one inpatient ICD-9 
Clinical Modification (ICD-9-CM) code or Current Procedural Terminology (CPT) code for 
coronary artery revascularization (i.e., percutaneous coronary intervention or coronary artery 
bypass graft). 
AC
CE
PT
ED
Copyright  201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.9 
INSOMNIA AND CVD IN HIV 8 
 
 Baseline covariates. Five groups of covariates were included, all of which were 
determined either using self-report questionnaire data collected at baseline or using routine 
clinical care data in the electronic medical record abstracted for the encounter closest to the 
participant’s enrollment date during the baseline period (i.e., -ever to +6 months of enrollment 
date). The specific ICD-9, ICD-9-CM, and CPT codes utilized in variable definitions are 
presented in Table 5, Supplemental Digital Content 2, http://links.lww.com/QAI/B279. First, 
demographic factors were age, sex (0=male, 1=female), and race/ethnicity (0=White, Hispanic, 
Other, 1=African American).  
Second, cardiovascular risk factors were hypertension, diabetes, body mass index (BMI), 
smoking, total cholesterol, and statin use. Blood pressure was defined as the average of the last 
three outpatient clinical measurements collected during routine clinical care closest to the 
enrollment date during the baseline period.43,44 Hypertension was categorized as no hypertension 
(blood pressure <140/90 mmHg and no antihypertensive medication [reference category]), 
controlled hypertension (<140/90 mmHg with antihypertensive medication), or uncontrolled 
hypertension (≥140/90 mmHg). Diabetes (yes/no) was identified by a previously validated metric 
incorporating glucose measurements, diabetes medication use, and/or at least one inpatient or 
two outpatient ICD-9 codes for diabetes.45,46 BMI (kg/m2) was defined by one outpatient clinical 
measurement collected during routine clinical care closest to the enrollment date during the 
baseline period and modeled as a continuous variable. Smoking (never [reference category], 
former, and current smoker) was assessed by self-report at enrollment. Total cholesterol was 
defined by one outpatient clinical measurement collected during routine clinical care closest to 
the enrollment date during the baseline period and modeled as a continuous variable. Baseline 
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statin use (yes/no) was defined as a filled prescription receipt for a 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitor at time of enrollment. 
Third, additional potential confounders were hepatitis C infection, renal disease, anemia, 
alcohol use, and cocaine use. Hepatitis C infection (yes/no) was identified by a positive hepatitis 
C virus antibody test or at least one inpatient or two outpatient ICD-9 codes for hepatitis C 
infection.47 Renal disease was defined by estimated glomerular filtration rate (eGFR),48 and 
anemia was defined using a hemoglobin; both were based on a measurement collected during 
routine clinical care closest to the enrollment date during the baseline period and were modeled 
as a continuous variables. Alcohol use was assessed by the Alcohol Use Disorders Identification 
Test (AUDIT-C) at baseline and alcohol abuse/dependence ICD-9 codes during the baseline 
period and dichotomized as no current use or non-hazardous use versus hazardous use (AUDIT-
C ≥ 4) or alcohol abuse/dependence disorder. Cocaine use was assessed by self-report at baseline 
and cocaine use disorder ICD-9 codes during the baseline period and dichotomized as never tried 
or no use in past 12 months versus use in the past 12 months or cocaine abuse/dependence 
disorder.  
Fourth, HIV-specific factors were HIV-1 RNA viral load, CD4+ T-cell count, and ART 
regimen. HIV-1 RNA viral load and CD4+ T-cell count were defined by outpatient clinical 
measurements collected during routine clinical care closest to the enrollment date during the 
baseline period and modeled as continuous variables. Baseline ART regimen (yes/no) was 
defined by a filled prescription receipt for any ART (-180 days to +7 days of enrollment date). 
Finally, insomnia-related variables were non-benzodiazepine sleep medication use, 
depressive symptoms, and antidepressant medication use. Non-benzodiazepine sleep medication 
use (yes/no) was defined by a filled prescription receipt closest to baseline (-ever to +180 days of 
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enrollment date) for the following medications: zolpidem, zaleplon, eszopiclone, and indiplon. 
Depressive symptoms were assessed by the PHQ-9 at baseline. Antidepressant medication use 
was defined by a filled prescription receipt for an antidepressant medication closest to baseline (-
ever to +180 days of enrollment date). We computed three dichotomous variables (yes/no) based 
on the antidepressant medication type – serotonin reuptake inhibitor (SSRI), tricyclic 
antidepressant (TCA), and miscellaneous other antidepressant.  
Statistical Analysis 
To examine the association between baseline insomnia symptoms and incident CVD 
events among HIV-infected veterans, first, we constructed Kaplan-Meier event-free survival 
curves to illustrate the time from enrollment to first CVD event for each of the five levels of our 
insomnia symptoms variable. Second, we constructed Cox proportional hazard regression models 
to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for each level of the 
insomnia symptoms variable (reference category: “No Difficulty Falling or Staying Asleep”), 
given our interest in the most clinically relevant insomnia symptoms group (“Bothers a Lot”) and 
the novelty of our research question in the HIV population. We also performed a likelihood ratio 
test of two Cox models (one with the insomnia symptoms variable and the other without) to 
present the overall significance of the insomnia symptoms variable. 
Five Cox proportional hazard regression models were constructed to hierarchically add 
the main covariates to create Model 4, our primary model, as follows: Model 0 – unadjusted 
(insomnia symptoms dummy coded variables alone predicting incident CVD); Model 1 – Model 
0 + demographics (age, sex, and race/ethnicity); Model 2 – Model 1 + CVD risk factors 
(hypertension, diabetes, BMI, smoking, total cholesterol, and statin use); Model 3 – Model 2 + 
additional potential confounders (hepatitis C infection, renal disease, anemia, alcohol use, and 
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cocaine use); and Model 4 – Model 3 + HIV-specific factors (HIV-1 RNA level, CD4+ T-cell 
count, and ART regimen).  
An additional four exploratory Cox proportional hazard regression models were 
constructed to examine the potential influence of insomnia-related variables. The first three Cox 
models hierarchically and individually added insomnia-related variables to Model 4 to examine 
the influence of each variable on Model 4. Three versions of Model 5 were constructed as 
follows: Model 5a – Model 4 + non-benzodiazepine sleep medication use; Model 5b – Model 4 + 
PHQ-9 total score; and Model 5c – Model 4 + SSRI use, TCA use, and miscellaneous other 
antidepressant use. The fourth Cox model included all of the covariates in one model as follows: 
Model 6 – Model 4 + non-benzodiazepine sleep medication use, PHQ-9 total score, SSRI use, 
TCA use, and miscellaneous other antidepressant use. 
We also conducted four exploratory sensitivity analyses. First, to examine the influence 
of adjusting for ART medications associated with insomnia or disruption of the metabolism of 
insomnia medications on our primary model,49,50 we re-ran two separate Model 4's. The first 
replaced the ART regimen variable with an efavirenz use variable (yes: n = 787; no: n = 2,321) 
and the second replaced the ART regiment variable with a protease inhibitor use variable (yes: n 
= 1,457; no: n = 1,651). Second, to examine the influence of omitting item 3 of the PHQ-9 
(“Trouble falling or staying asleep, or sleeping too much”) on models including depression, we 
removed the item from the PHQ-9 total score calculation and re-ran Model 5b and Model 6. 
Multiple imputations using chained equations with five separate imputed datasets were 
generated based on predictive mean matching using the Hmisc library of R programming 
language. Cox survival models were fitted in each imputed dataset and then combined to obtain 
pooled HRs and standard errors. All analyses were performed using R software (version 3.3.3; 
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www.r-project.org). To account for inflation in type 1 error associated with multiple tests, we 
considered p < .01 as statistically significant. 
 
Results 
Participant Characteristics 
Participant characteristics are shown in Table 1. The median age was 49 years. Most 
participants were men (97%), and two-thirds were African American (66%). The distribution of 
participants and incident CVD events across insomnia symptom categories are displayed in 
Table 2. At enrollment, the majority of HIV-infected veterans endorsed some level of insomnia 
symptoms (59%). During a median follow-up time of 10.8 years (1st quartile: 6.7, 3rd quartile: 
11.8), 267 incident CVD (8.6%) events occurred. 
Baseline Insomnia Symptoms and Incident CVD Events 
Figure 1 presents Kaplan-Meier survival curves illustrating the time to first CVD event 
for each of the five insomnia symptom categories. For HIV-infected veterans, the “Bothers a 
Lot” survival curve consistently separates from those for the other four categories around the 
sixth year of follow-up. Though visually supporting a difference in time to CVD event between 
“Bothers a Lot” and the other four categories, this is not reflected in the omnibus test of the 
survival curves (log-rank χ2 = 5.2, df = 4, p = .267). 
The five Cox models constructed to hierarchically create our primary Model 4 examining 
the association between baseline insomnia symptoms and incident CVD events revealed that the 
test of overall significance across the four insomnia symptoms dummy coded variables was not 
significant in Models 0-4 (p-value range: .069-.304; Table 3). These omnibus null results were 
driven by the lack of associations between incident CVD events and the dummy coded variables 
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comparing the “Doesn’t Bother,” “Bothers a Little,” and “Bothers” groups to the “No difficulty 
Falling or Staying Asleep” group in Model 0-4 (p-value range: .305-.971). In contrast, the 
dummy coded variable comparing the “Bothers a Lot” group to the “No difficulty Falling or 
Staying Asleep” group fell just short of significant in Model 0 (p = .034) and was significantly 
associated with incident CVD in Models 1-4 (HR range: 1.45-1.70; p-value range: .003-.007). To 
illustrate, our primary Model 4 results indicate that HIV-infected veterans bothered a lot by 
difficulty falling or staying asleep had a 66% greater risk of incident CVD events than HIV-
infected veterans without these symptoms, independent of demographics, CVD risk factors, 
additional potential confounders, and HIV-specific factors.  
 The four additional exploratory Cox models constructed to hierarchically examine the 
potential influence of insomnia-related variables revealed similar results to Models 0-4 for the 
overall significance across the four insomnia symptoms dummy coded variables in Models 5a-5c 
and Model 6 (p-value range: .147-.591; Table 3) and the dummy coded variables comparing the 
“Doesn’t Bother,” “Bothers a Little,” and “Bothers” groups to the “No difficulty Falling or 
Staying Asleep” group in Model 5a-5a and Model 6 (p-value range: .360-.933). Similar to Model 
4, the dummy coded variable comparing the “Bothers a Lot” group to the “No difficulty Falling 
or Staying Asleep” group remained significantly associated with incident CVD after including 
non-benzodiazepine sleep medication use in Model 5a (62% greater risk; p = .009). However, the 
“Bothers a Lot” and “No difficulty Falling or Staying Asleep” group comparison fell short of 
significance after including PHQ-9 total score in Model 5b (51% greater risk; p = .060), 
antidepressant medication use in Model 5c (51% greater risk; p = .031), or all three insomnia-
related variables in Model 6 (42% greater risk, p = .115). 
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Results of the four exploratory sensitivity analyses are presented in Table 4, 
Supplemental Digital Content 1, http://links.lww.com/QAI/B279. Our first and second sensitivity 
analyses, in which ART regimen was replaced with either efavirenz use or protease inhibitor use 
in Model 4, yielded nearly identical results (Bothers a Lot HR in Model 4 with efavirenz use = 
1.68, 95%CI: 1.17-2.39, p = .005; Bothers a Lot HR in Model 4 with protease inhibitor use = 
1.67, 95%CI: 1.17-2.39, p = .004) to our original Model 4. Our third and fourth sensitivity 
analyses, in which the sleep disturbance item was omitted from the PHQ-9 total score calculation 
in Models 5b and 6, also produced nearly identical results (Bothers a Lot HR in Model 5b = 1.53, 
95%CI: 1.02-2.32, p = .042; Bothers a Lot HR in Model 6 = 1.43, 95%CI: 0.94-2.17, p = .093) to 
our original Models 5b and 6. These findings indicate that (a) adjusting for ART medications 
with recognized effects on insomnia or insomnia medications and (b) removing the sleep 
disturbance item from the depressive symptoms measure had a negligible influence on the 
relationships of interest. 
Discussion 
In this large prospective cohort study utilizing the VACS-Survey Cohort data, we found 
that insomnia symptoms were associated with incident CVD among HIV-infected veterans. After 
adjustment for demographics, CVD risk factors, additional potential confounders (hepatitis C 
infection, renal disease, anemia, alcohol use, and cocaine use), and HIV-specific factors (HIV-1 
RNA level, CD4+ T cell count, and ART regimen), HIV-infected veterans bothered a lot by 
difficulty falling or staying asleep exhibited a 66% greater risk of an incident CVD event than 
HIV-infected veterans without these symptoms. This association persisted after individually 
adjusting for non-benzodiazepine sleep medication use (62% greater risk). However, while the 
hazard ratios were similar in magnitude (HRs = 1.51), the association between highly 
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bothersome insomnia symptoms and incident CVD fell short of significance after individually 
adjusting for depressive symptoms or antidepressant medication use. We did not observe 
associations between the other insomnia symptoms category comparisons (“Doesn’t Bother,” 
“Bothers a Little,” and “Bothers” versus “No Difficulty Falling or Staying Asleep”) and incident 
CVD events. Taken together, the present results suggest that highly bothersome insomnia 
symptoms may be an independent predictor of incident CVD events among HIV-infected adults, 
although the overlap with depression and its treatment needs further investigation. 
To our knowledge, this is the first examination of the insomnia-CVD relationship in 
people with HIV. We observed a threshold effect, with only the highest level of insomnia 
symptoms exhibiting an elevated CVD risk. The leading potential explanation for this finding is 
that (a) the “Bothers a Lot” group may have the highest rate of insomnia disorder and that (b) it 
is insomnia disorder, but not subclinical insomnia symptoms, that is related to elevated CVD 
risk. Future studies are needed to evaluate this possibility.  
The biological plausibility of the insomnia-CVD relationship in the HIV population has 
preliminary support. Insomnia symptoms have been associated with inflammation-related single 
nucleotide polymorphisms51,52 and elevated circulating levels of interleukin-6 and CRP,53 both of 
which are implicated in atherosclerosis among HIV-infected adults.54 Additional support for the 
insomnia-CVD relationship can be drawn from the general population literature, as three meta-
analyses have linked insomnia symptoms with future CVD.23-25 In addition, general population 
evidence supports associations between insomnia symptoms and biological mechanisms 
underlying CVD development, including systemic inflammation,31 altered coagulation,32-38 and 
endothelial dysfunction.55-57  
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 There are study limitations that warrant consideration. First, our insomnia symptoms 
assessment was obtained only at baseline and relied on a single item. While the VACS HIV 
Symptom Index’s42 insomnia item does assess difficulty initiating or maintaining sleep and 
bothersomeness, it misses other insomnia symptoms (e.g., early morning awakening and 
functional impairment), and it does not measure frequency or duration. These content validity 
issues could lead to misclassification (e.g., coding a veteran with insomnia symptoms as not 
having them), which could contribute to effect size underestimation. That said, the majority of 
general population studies have used single-item insomnia assessments (most often assessing 
difficulty falling asleep) and have observed positive associations with CVD-related outcomes.24 
In addition, the insomnia symptoms item does not capture chronicity of insomnia. Future 
research should examine the potential influence of insomnia duration or chronic versus acute 
insomnia on incident CVD risk. Second, because we utilized a veteran sample comprised of 
mostly men, it is unclear whether our results extend to HIV-infected women. Third, due to the 
timeframe of this study, we could not assess for newer ART therapies linked to insomnia – 
namely, rilpivirine and dolutegravir. Fourth, due to the absence of a strong assessment, we were 
unable to adjust our models for sleep apnea – a sleep disorder with an estimated prevalence of 
2.9% among veterans58 and an established independent risk factor for incident CVD.59 Fifth, we 
were unable to include posttraumatic stress disorder (PTSD) as a potential confounder. Some of 
the symptoms of PTSD have strong conceptual and measurement overlap with the insomnia 
symptoms of interest here (i.e., nightmares and difficulty sleeping due to alterations in arousal 
and reactivity)60 and the available PTSD assessments do not allow for the separation of insomnia 
and PTSD symptoms. Future research should examine include comprehensive measures of 
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insomnia and PTSD symptoms in order to tease apart the potential influence of these overlapping 
factors on incident CVD. 
In summary, we provide intriguing evidence that highly bothersome insomnia symptoms 
may be an independent predictor of incident CVD events among HIV-infected adults. Future 
prospective studies with comprehensive insomnia assessments utilizing non-veteran samples are 
needed to fully characterize the insomnia-CVD relationship and to identify its underlying 
mechanisms in the HIV population. Ultimately, such research could lead to the identification of a 
novel, modifiable risk factor for HIV-CVD and could inform the development of new primary 
prevention programs that include insomnia interventions to prevent CVD in people with HIV.  
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Figure Legend 
Figure 1. Kaplan-Meier survival curves illustrating the time to first incident CVD event over a 
median follow-up of 10.8 years for HIV-infected Veterans (N = 3,108; log-rank χ2 = 5.2, df = 4, 
p = .267). 
CVD = cardiovascular disease; HIV = human immunodeficiency virus 
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Table 1 
Baseline Characteristics of HIV-Infected VACS-Survey Cohort Participants (N = 
3,108) 
Age, years 49.0 [43.3, 54.6] 
Sex, % Male 3,018 (97.1) 
Race/ethnicity, % African American 2,059 (66.2) 
Hypertensiona  
None 1,376 (44.3) 
Controlled 1,033 (33.2) 
Uncontrolled 699 (22.5) 
Diabetes 390 (12.5) 
BMI, kg/m2 25.2 [22.6, 28.1] 
Smokinga  
Current 1,619 (52.3) 
Former 727 (23.5) 
Never 749 (24.2) 
Total Cholesterola, mg/dL 173 [148, 203] 
Statin Use 468 (15.1) 
Hepatitis C Infection 1,064 (34.3) 
eGFRa, mL/min/1.73m2 97.0 [82.6, 113.3] 
Hemoglobina , g/dL 13.9 [12.8, 15.0] 
Alcohol Usea   
No current use or non-hazardous use 1,905 (61.5) 
Hazardous use or abuse/dependence 1,192 (38.5) 
Cocaine Usea  
Never tried or no past-year use 2,430 (77.5) 
Past-year use or abuse/dependence 678 (22.5) 
Non-benzodiazepine Sleep Medication 203 (6.5) 
PHQ-9 Total Scorea 4 [1, 9] 
Antidepressant Medication  
SSRI 1,037 (33.4) 
TCA 621 (20.0) 
Miscellaneous 1,010 (32.5) 
HIV-1 RNAa, copies/mL 400.0 [75.0, 14667.7] 
CD4+ T Cell Count a 370.0 [218.0, 552.0] 
ART regimen 2,490 (80.1) 
Note. Continuous variables are presented as median [first quartile, third quartile]. 
Dichotomous/categorical variables are presented as n (%). VACS = Veterans Aging Cohort Study; 
HIV = human immunodeficiency virus; BMI = body mass index; eGFR = estimated glomerular 
filtration rate; PHQ-9 = Patient Health Questionnaire-9; SSRI = selective serotonin reuptake 
inhibitor; TCA = tricyclic antidepressant; ART = antiretroviral therapy. 
aThe following variables include fewer than 3,108 participants because of missing data (n, % 
missing): BMI (11, 0.4%), smoking (13, 0.4%), total cholesterol (154, 5%), eGFR (5, 0.2%), 
hemoglobin (4, 0.1%), alcohol use (11, 0.4%), cocaine use (94, 3%), HIV-1 RNA (14, 0.5%), and 
CD4+ cell count (12, 0.4%). 
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Table 2 
HIV-Infected VACS-Survey Cohort Participants and Incident CVD Events across 
Baseline Insomnia Symptom Categories 
Baseline Insomnia 
Symptoms 
Total Cases Incident CVD Cases 
n % n % 
N = 3,108 --- --- 267 8.6 
No Difficulty Falling or 
Staying Asleep 1,270 40.9 103 8.1 
Doesn’t Bother 285 9.2 24 8.4 
Bothers a Little 643 20.7 52 8.1 
Bothers 465 15.0 40 8.6 
Bothers a Lot 445 14.3 48 10.8 
Note. VACS-SC = Veterans Aging Cohort Study; CVD = cardiovascular disease; HIV = human 
immunodeficiency virus. 
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 Table 3 
Cox Proportional Hazards Regression Models Examining the Association Between 
Baseline Insomnia Symptom and Incident CVD Events in the HIV-Infected VACS-Survey 
Cohort Participants (N = 3,108) 
Model HR (95% CI) p-value 
Model 0: Unadjusted  .304 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.01 (0.65, 1.58) .951 
Bothers a Little 1.01 (0.72, 1.41) .962 
Bothers 1.14 (0.79, 1.65) .470 
Bothers a Lot 1.45 (1.03, 2.04) .034 
Model 1: Demographics  .099 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.05 (0.67-1.63) .844 
Bothers a Little 1.08 (0.77-1.51) .650 
Bothers 1.21 (0.84-1.75) .305 
Bothers a Lot 1.64* (1.16-2.31) .005 
Model 2: CVD Risk Factors  .114 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.01 (0.65-1.58) .971 
Bothers a Little 1.05 (0.75-1.47) .778 
Bothers 1.15 (0.79-1.66) .465 
Bothers a Lot 1.62* (1.14-2.30) .007 
Model 3: Additional Potential Confounders  .069 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.03 (0.66-1.62) .883 
Bothers a Little 1.07 (0.76-1.49) .704 
Bothers 1.21 (0.83-1.76) .315 
Bothers a Lot 1.70* (1.19-2.43) .003 
Model 4: HIV-Specific Factors  .104 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.06 (0.68-1.67) .787 
Bothers a Little 1.08 (0.77-1.51) .667 
Bothers 1.21 (0.83-1.76) .321 
Bothers a Lot 1.66* (1.16-2.37) .005 
Model 5a: Non-Benzodiazepine Sleep 
Medication Use 
 
.147 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.06 (0.68-1.66) .795 
Bothers a Little 1.07 (0.76-1.50) .699 
Bothers 1.19 (0.82-1.74) .360 
Bothers a Lot 1.62* (1.13-2.32) .009 
Model 5b: PHQ-9 Total Score  .443 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.04 (0.66-1.64) .856 
Bothers a Little 1.05 (0.74-1.48) .791 
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Bothers 1.14 (0.76-1.71) .516 
Bothers a Lot 1.51 (0.98-2.32) .060 
Model 5c: Antidepressant Medication Use  .309 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.06 (0.68-1.66) .797 
Bothers a Little 1.03 (0.73-1.45) .856 
Bothers 1.12 (0.76-1.65) .552 
Bothers a Lot 1.51 (1.04-2.19) .031 
Model 6: All Covariates  .591 
No Difficulty Falling or Staying Asleep 1.00 --- 
Doesn’t Bother 1.05 (0.67-1.64) .846 
Bothers a Little 1.01 (0.72-1.43) .933 
Bothers 1.09 (0.72-1.63) .694 
Bothers a Lot 1.42 (0.92-2.19) .115 
Note. The p-value for the test of overall significance across the four insomnia symptoms dummy coded 
variables is displayed in respective model row. CVD = cardiovascular disease; VACS-SC = Veterans Aging 
Cohort Study; HIV = human immunodeficiency virus; HR = hazard ratio; CI = confidence interval; PHQ-9: 
Patient Health Questionnaire-9; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic 
antidepressant. 
Model 0: Unadjusted (insomnia symptoms dummy coded variables alone predicting incident CVD) 
Model 1: Demographics (age, sex, race/ethnicity) 
Model 2: CVD Risk Factors (Model 1 + hypertension, diabetes, BMI, smoking, total cholesterol, statin use) 
Model 3: Additional Potential Confounders (Model 2 + hepatitis C infection, renal disease, anemia, alcohol 
use, cocaine use) 
Model 4: HIV-Specific Factors (Model 3 + HIV-1 RNA level, CD4+ T-cell count, ART regimen) 
Model 5a: Non-Benzodiazepine Sleep Medication Use (Model 4 + non-benzodiazepine sleep medication use) 
Model 5b: PHQ-9 Total Score (Model 4 + PHQ-9 total score)  
Model 5c: Antidepressant Medication Use (Model 4 + SSRI use, TCA use, and miscellaneous/other 
antidepressant use) 
Model 6: All Covariates (Model 4 + non-benzodiazepine sleep medication use, PHQ-9 total score, SSRI use, 
TCA use, and miscellaneous other antidepressant use) 
*p < .01 
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